Fig. 3
From: Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN
Preparation and characterization of anti-CD79B-scFv-OA2-siRAPSYN. a Agarose gel electrophoresis of OA2 and scFv-OA2 loaded with siRNA at N/P ratio of 5. b TEM images of OA2, OA2-siRAPSYN, scFv-OA2 and scFv-OA2-siRAPSYN (scale: 50 μm). c Stability of different lipid nanoparticles in saline and medium containing 10% (v/v) FBS. d Flow cytometry of cellular uptake of FAM-siRNA via different formulations by K562 cells. Statistical analysis was based on MFI values (n = 3). e The separation between lysosomes (red) and intracellular FAM-siRNA (green) in K562 cells under fluorescent microscope (scale: 5 μm). f Comparisons of mRNA levels of RAPSYN after the treatment of different formulations. Data are presented as mean ± SD (n = 3). ns: no significance, *P < 0.05, **P < 0.01 versus control; ###P < 0.001,##P < 0.01 versus scFv-OA2